Immunobiology and immunotherapeutic targeting of glioma stem cells

Advances in Experimental Medicine and Biology

Volumn 853, Issue , 2015, Pages 139-166

  Madany, Mecca ^a   Thomas, Tom M ^a   Edwards, Lincoln ^a   Yu, John S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer immunology; Cancer stem cells; Glioblastoma; Glioma stem cells; Immunotherapy

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CD133 ANTIGEN; CD15 ANTIGEN; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ICT 107; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; MONOCLONAL ANTIBODY; PANITUMUMAB; PEPTIDE VACCINE; PLACEBO; PSEUDOMONAS EXOTOXIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SOX6; TRASTUZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; IMMUNOBIOLOGY; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SERIAL ANALYSIS OF GENE EXPRESSION; ADULT; ANIMAL; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); GLIOMA; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES;

ADULT; ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; IMMUNOTHERAPY; NEOPLASTIC STEM CELLS;

EID: 84928547630     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-16537-0_8     Document Type: Article

References (129)

1. Allegra A, Alonci A, Penna G, Innao V, Gerace D, Rotondo F, Musolino C. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest. 2014;32(9):470–95. doi: 10.3109/07357907.2014.958231.
2. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature. 2004;432:396–401
4. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma-stem like cells give rise to tumor epithelium. Nature. 2010;468:829–35
5. Cheng L, Huang Z, Zhou W, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013;153(1):139–52
6. Lathia JD, et al. High-throughput fl ow cytometry screening reveals a role for junctional adhesion molecule as a cancer stem cell maintenance factor. Cell Rep. 2014;6(1):117–29
7. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226–35
8. Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39:193–206
9. Xiangpeng Y, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23:9392–400
10. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391–403
11. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122(4):761–8
12. Joo KM, Kim SY, Song SY, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008;88(4):808–15
13. Barcelos LS, Duplaa C, Krankel N, et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res. 2009;104(9):1095–102
14. Jin Son M, Woolard K, Nam D-H, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4(5):440–52
15. Anido J, Saez-Borderias A, Gonzalez-Junca A, et al. TGF-β receptor inhibitors target the CD44 high /Id1 high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18:655–68
16. Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep. 2010;10(4):259–66
17. DeVita VT, Hellstrom S, Rosenberg SA. Biologic therapy of cancer, vol. 2. Philadelphia: J. B. Lippincott Company; 1995
18. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fl uid in the interstitial compartment of mammary tumors. Cancer Res. 1975;35(11 Pt 1):3084–8. PubMed: 1182701
19. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macro-molecules in tumors: signifi cance of elevated interstitial pressure. Cancer Res. 1988;48(24 Pt 1):7022–32. PubMed: 3191477
20. Williams LE, Duda RB, Proffi tt RT, Beatty BG, Beatty JD, Wong JY, Shively JE, Paxton RJ. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med. 1988;29(1):103–9
21. Wikstrand CJ, Cokgor I, Sampson JH, et al. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 1999;18(4):451–64
22. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convectionenhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994; 91(6):2076–80
23. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol. 1999;11(5):541–7
24. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 2008;47(1):9–19
25. Ohno M, Natsume A, Ichiro Iwami K, et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 2010;101(12):2518–24
26. Eller JL, Longo SL, Hicklin DJ, et al. Activity of antiepidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. 2002;51(4):1005–14
27. Faillot T, et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery. 1996;39:478–83
28. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997;57(18):4130–40
29. Zalutsky MR, Boskovitz A, Kuan CT, et al. Radioimmuno targeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol. 2012;39(1):23–34
30. Yang W, Barth RF, Wu G, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res. 2005;11(1):341–50
31. Perera RM, Narita Y, Furnari FB, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor- specifi c antibody generates enhanced antitumor activity. Clin Cancer Res. 2005;11(17):6390–9
32. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12):4119–24
33. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19(56):6550–65
34. Gilbert MR, Dignam J, Won M, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating Bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31 (suppl;abstr 1).
35. Day ED, Lassiter S, Woodhall B, Mahaley JL, Mahaley MS. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res. 1965;25(6):773–8
36. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer. 2004;90(8):1469–73
37. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human gliomamesenchymal extracellular matrix antigen defi ned by monoclonal antibody. Cancer Res. 1983;43(6):2796–805
38. Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specifi c monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55(23 Suppl):5952s–6
39. Rosenkranz AA, Vaidyanathan G, Pozzi OR, Lunin VG, Zalutsky MR, Sobolev AS. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. Int J Radiat Oncol Biol Phys. 2008;72(1):193–200
40. De Vita Jr VT, Lawrence TS, Rosenberg SA, et al., editors. Cancer: principles & practice of oncology. 9th ed. Philadelphia, PA: LWW; 2011
41. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 1996;56(24):5631–7
42. Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol. 2005;7(1):90–6
43. vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell mediated glioma rejection. J Exp Med. 2013;210:2803–11
44. Hayes RL, Arbit E, Odaimi M, et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol. 2001;39(1–2):31–42
45. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823–41
46. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg. 1988;208:121–35
47. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41(11 Pt 1):4420–5
48. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg. 1986;64(1):114–7
49. Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–85
50. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specifi c recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160–6
51. Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009;94(3):373–82
52. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215-172
53. Steinman RM, Cohn ZAJ. J Exp Med. 1973;137:1142–62
54. Badhiwala J, Decker WK, Berens ME, Bhardwaj RD. Clinical trials in cellular immunotherapy for brain/CNS tumors. Expert Rev Neurother. 2013;13(4):405–24
55. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol. 2012;2012:425–76
56. Ali-Osman F. Brain tumors. In: Masters JRW, Palson B, editors. Human cell culture, vol. 2. New York, NY: Kluwer Academic Publishers; 1999. p. 167–84
57. Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol. 1999;11(2):125–37
58. Decker WK, Xing D, Shpall EJ. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant. 2006;12(2):113–25
59. Li Z, Lee JW, Mukherjee D, et al. Immunotherapy targeting glioma stem cells—insights and perspectives. Expert Opin Biol Ther. 2012;12(2):165–78
60. Yamanaka R, Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin Biol Ther. 2007;7:645–9
61. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is effi cacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247–54
62. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res. 1999;5(5):985–90
63. Shimato S, Natsume A, Wakabayashi T, Tsujimura K, Nakahara N, Ishii J, Ito M, Akatsuka Y, Kuzushima K, Yoshida J. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J Neurosurg. 2008;109(1):117–22
64. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H. Human cytotoxic T-lymphocyte responses specifi c for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics. 2000;51(2):99–107
65. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008;116(1):79–86
66. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel gliomaassociated antigen peptides and clinical activity by vaccinations with{α}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330–6
67. Huang J, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecifi c antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol (Orlando, Fla). 2013;149(1):156–68
68. Ikegame A, et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia. 2012;26(9):2124–34
69. Schlaak M, et al. Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget. 2012;3(1):22–30
70. Ueda R, et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer. 2010; 126(4):919–29
71. Xu Q, et al. Antigen-specifi c T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells (Dayton, Ohio). 2009;27(8):1734–40
72. Xiao ZY, et al. An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biol Ther. 2011;11(11):974–80. Web. 21 Mar. 2014
73. Pellegatta S, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 2006;66(21):10247–52
74. Ning N, et al. Cancer stem cell vaccination confers signifi cant antitumor immunity. Cancer Res. 2012;72(7):1853–64. Web. 21 Mar. 2014
75. Natsume A, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008;122(11):2542–53. Web. 21 Mar. 2014
76. Odunsi K, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63(18):6076–83
77. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokineactivated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986;46(4 Pt 2):2101–4
78. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfi eld EH. Intratumoral LAK cell and interleukin- 2 therapy of human gliomas. J Neurosurg. 1989;70(2):175–82
79. Blancher A, Roubinet F, Grancher AS, et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw. 1993;4(5):331–41
80. Boiardi A, Silvani A, Ruffi ni PA, et al. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother. 1994;39(3):193–7
81. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin- 2. Cancer. 1988;62(4):665–71
82. Merchant RE, Merchant LH, Cook SH, McVicar DW, Young HF. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery. 1988;23(6):725–32
83. Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokineactivated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol. 1996;27(2):133–40
84. Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front Oncol. 2013;3:275
85. Yoshida S, Tanaka R, Takai N, Ono K. Local administration of autologous lymphokineactivated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 1988;48(17):5011–6
86. Okamoto Y, Shimizu K, Tamura K, et al. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir. 1988;94(1–2): 47–52
87. Dillman RO, Duma CM, Schiltz PM, et al. Intracavitary placement of autologous lymphokineactivated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27(5):398–404
88. Dillman RO, Duma CM, Ellis RA, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009;32(9):914–9
89. Kitahara T, Watanabe O, Yamaura A, et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specifi c for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol. 1987;4(4):329–36
90. Kruse CA, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997;45(2):77–87
91. Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res. 2003;9(9):3294–302
92. Tsurushima H, Liu SQ, Tuboi K, et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn J Cancer Res. 1999;90(5):536–45
93. Quattrocchi KB, Miller CH, Cush S, et al. Pilot study of local autologous tumor infi ltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999;45(2):141–57
94. Holladay FP, Heitz-Turner T, Bayer WL, Wood GW. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/ IV astrocytoma. J Neurooncol. 1996;27(2):179–89
95. Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998;89(1):42–51
96. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000;6(6):2209–18
97. Sloan AE, Dansey R, Zamorano L, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte– macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus. 2000;9(6):e9
98. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent Grade III/IV astrocytoma. J Neurooncol. 2000;48(2):113–20
99. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother. 2008;57(3):425–39
100. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10(1):10–8
101. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347–50
102. Dziurzynski K, Wei J, Qiao W, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011;17(14):4642–9
103. Ishikawa E, Tsuboi K, Yamamoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci. 2007;98(8):1226–33
104. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specifi c immunization with modifi ed tumor cell vaccine in glioblastoma multiforme. J Neurooncol. 2001;53(1):39–46
105. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefi t. J Clin Oncol. 2004;22(21):4272–81
106. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50(7):337–44
107. Yu JS, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial t-cell infi ltration. Cancer Res. 2001;61(3): 842–7
108. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysatepulsed dendritic cells elicits antigen-specifi c, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–9
109. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68(14):5955–64
110. Fadul CE, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (Hagerstown, Md 1997). 2011;34(4):382–9
111. Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 2012;62(1):91–9
112. Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a Phase II clinical trial. World Neurosurg. 2012;77(5–6):736–44
113. Westphal M, Ferdinand B. Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide. J Clin Oncol. 2012;30(Suppl):abstr 2033. Web. 28 July 2014
114. Wen PY, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. J Clin Oncol. 2014;32(5s Suppl):abstr 2005. Web. 28 July 2014
115. Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 2005; 11(16):5900–11
116. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108(5):963–71
117. Morita S, Oka Y, Tsuboi A, et al. A Phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the Phase I data. Jpn J Clin Oncol. 2006;36(4):231–6
118. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specifi c immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324–33
119. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression- free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–9
120. Crane CA, Han SJ, Ahn B, et al. Individual patient-specifi c immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19(1):205–14
121. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe- Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62(9):1499–509
122. Bigner DD, Brown M, Coleman RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14F(ab′)2—a preliminary report. J Neurooncol. 1995;24(1):109–22
123. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 1995;15(3):244–56
124. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991;115(4):1127–36
125. Neyns B, Sadones J, Joosens E, et al. Stratifi ed phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596–603
126. Gil-gil JM, et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 2013;7:123–35
127. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J. 2008;14(5):279–85
128. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142–8
129. Gilbert MR, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2013;31.